Alzheon
Framingham
About Alzheon
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated with neurodegeneration. They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $366.2M
- Funding stage: Late Stage Venture
- Last round: Series E (Jun 2024)
- Website: alzheon.com
- Phone: +1 857 214-7242
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alzheon-78841 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.